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Immune memory has been explained according to three basic  schemes:  (a) 
altered handling of antigen due to combination with antibody or due to the 
ability of macrophages to degrade antigen more effectively; (b) expansion of a 
done of reactive ceils,  the daughter cells being identical to the original anti- 
gen-sensitive cells (1-3); and (c)  differentiation of a unique class of "memory 
cells" which react more rapidly and  effectively on antigen contact than the 
original antigen-sensitive cells (4-7). In this paper we examine the establish- 
ment of short-term memory to distinguish between these hypotheses. We define 
memory as the capacity to give a greater and more rapid response to a  second 
injection of antigen than to a first injection. In the response of mice to sheep 
erythrocytes (SRBC), measured by the hemolytic plaque assay (8), early IgM 
memory arises within the 1st day, approximately 2 days before any substantial 
increase in direct plaques (9). IgM memory continues to increase during the 
1st wk after the primary injection (9, 10). 
We sought to determine whether this early establishraent of memory could 
occur in the presence of an antimetabolite which prevents cell division by in- 
hibiting  thymidine  synthesis,  methotrexate  (11).  The  results  indicate  that 
antigen-sensitive cells undergo a  qualitative change during the 1st day after 
primary stimulation and, on further antigen contact, begin to divide. There is 
no such nonproliferative lag phase after a secondary injection. 
Materials and Methods 
Mice.--A/Jax  mice were bred in our laboratory from Jackson Laboratories stock (Bar 
Harbor, Me.). Animals of both sexes, 6-10 wk old, were used in each group. 
An/ggen.--Sheep blood in Alsever's solution was  purchased from Mission Laboratory 
Supply, Inc., Rosemead, Calif., and used within 3 wk. Erythrocytes were washed and re- 
uspended in saline, then injected into the retroorbital plexus (12). 
Drugs.mMethotrexate, sodium (American Cyanamid Co., Lederle Laboratories Division, 
Pearl River, N.Y.) 25 mg/kg body weight and folinic  acid (leucovorin,  Lederle) 25-35 mg/kg 
were injected intraperitoneally.  Hydroxyurea (Nutritional Biochemicals  Co.,  Cleveland,  Ohio) 
was used in doses of 0.05-2.5 mg/kg, injected intraperitoneally. 
Preparation of Cell Suspens~ons.--Mice were killed~ their spleens  were removed and minced 
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with scalpels in Eagle's minimal essential medium without bicarbonate (pH adjusted to 7.4 
with NaOH). The suspension was passed through two stainless steel screens, 80 and 250 
mesh, respectively. Nucleated cells were counted in a hemacytometer after dilution into a 
hemolytic agent, 0.01% gentian violet, 2% acetic acid. In most experiments,  the total volume 
of the cell suspension was recorded in order to calculate the plaques per spleen. 
Hemolytic Assays.--Hemolytic plaque assays were performed by a modification of the 
technique of Jerne and Nordin (8). To 0.75 ml 0.7% agarose, dissolved in Eagle's minimal 
essential medium,  were added  0.04 m120% washed sheep  erythrocytes,  0.04  ml guinea pig serum 
(complement), and a variable amount of spleen cell suspension. This mixture was poured 
onto a  1.4%  agarose-Eagle's minimal essential medium underlayer in a 50 mm Petri dish 
and incubated 2-3 hr at 37°C. Plaques were counted by indirect light. 
RESULTS 
Early IgM Memory.--Memory is defined as the number of plaques resulting 
from two injections of antigen minus  the sum of the plaques expected from 
either injection alone. Our standard dose regimen was an injection of 2 X  10  e 
SRBC ("low" dose), followed at varying intervals by an injection of 4  X  l0  s 
SRBC ("high" dose). The total response and the calculated memory for several 
dose regimens are shown in Table I. The primary response to either the high or 
the low dose alone is included for reference. Also included axe our code designa- 
tions for each group. 
During the first 2 days of the response to either dose alone, there is little in- 
crease in the number of direct plaques (see groups 2L and 2H in Table I). Dur- 
ing this  period, however, the mice have become able to respond much more 
rapidly and vigorously to a  second dose of antigen;  that is,  they have been 
primed. Comparing group 1,2 with groups receiving only the primary injection 
(3L) or only the secondary injection (2H), it is apparent that the injections 
elicit a far greater response in combination than alone. The memory increases 
further during the 2nd day after primary injection: the memory value is larger 
for group 2,2 than for group 1,2 (see reference 9). 
Cell Division and the Immune Response.--We  employed methotrexate (MTX), 
a folio acid antagonist, to prevent cell division. Folinic acid (leueovorin =  LV) 
was injected 24 hr after MTX in an attempt to prevent further inhibition and 
increase the general health of the animals, although most of the MTX should 
have been excreted by this time (13). LV is an effective antidote when adminis- 
tered simultaneously with MTX but has little effect when administered 1 day 
later (Table II, and reference 14). 
There is a  striking contrast between the first and subsequent days of the 
response of mice to SRBC.  MTX administered simultaneously with antigen 
(or before antigen) does not inhibit the response to a high dose of SRBC (Table 
II). However, MTX administered after 1 or 2 days have elapsed greatly dimin- 
ishes the plaque number. The same disparity between the first and subsequent 
days is apparent in the response to a low dose of SRBC; MTX administered PATRICIA  BYFIELD  AND  ELI  SERCAP.Z  899 
TABLE  I 
The Plaque Response to a Low Dose and a High Dose of SRBC,*  and Combinations Thereof, 
with Calculations of Immune Memory 
Code~  Primary  dose 
Background 
,  ]  -- 
Low primary 
2L  Low 
3L  Low 
4L  Low 
5L  Low 
~-ligh primary 
2H  High 
3H  High 
4H  High 
~econdary 
1,1  Low 
1,2  Low 
1H,2  High 
1,3  Low 
2,1  LOw 
2,2  Low 
~ultiple 
3 Daily low doses 
4 Daily low doses 
Time 
Time be-  Secondary  tween  last  No. of  tween  injections  dose  injection  mice  and assay 
days  days 
Plaques/10s  Memory§ 
spleen cells 
Mean  Antilog  Plaques/10e  logs  spleen  cells 
5  0  1  -- 
2  5  1.0  2  -- 
--  3  10  1.0  2  -- 
--  4  14  4.4  21  -- 
5  10  5.7  51  -- 
2  10  1.5  2.8  -- 
3  34  5.3  39 
--  4  13  8.0  256  -- 
High  1  6  2.1  4.3  2 
High  2  19  5.3  39  35 
High  2  8  6.5  90  49 
High  3  5  7.6  194  134 
High  1  8  2.8  7  5 
High  2  35  6.8  111  88 
7  4.4  21  17 
9  6.9  119  94 
* A  low dose is 2 X  los SRBC. A high dose is 4 X  l0  s SRBC. 
In a series, the primary injection is a low dose and the secondary, high, unless otherwise 
indicated. For example, mice in group 2,2 received 2 X  l0  s SRBC on day 0, 4  X  l0  s SRBC 
on day 2, and were killed day 4. 
§ "Memory" was calculated by subtracting from  the plaques obtained the sum  of  all 
plaques expected as a result of either injection alone. This is not applicable in groups receiv- 
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simultaneously with antigen (on day 0) has no effect, but MTX administered 
on day 1, 2, or 3 decreases the 4-day plaque response 8- to 15-fold (Fig. 1, A). 
Cell Division and the Establishment of Memory.--The effect of MTX on the 
establishment of short-term memory was examined in mice which received a 
second antigenic challenge 2 days after the primary injection. MTX was ad- 
ministered on day 0,  1,  2, or 3  relative to the primary injection,  and the re- 
sponse was measured on day 4 (Fig. 1, B). Two conclusions can be drawn from 
this experiment. (a) MTX does inhibit the events occurring within 24 hr after a 
secondary injection of antigen. This is in contrast to its lack of effect during the 
1st day of a primary response. (b) Priming, like the primary response itself, be- 
TABLE II 
Effect of Metkotrexate on the 3-Day Response of Mice to a High Dose* of Sheep Erytkroeytes 
Dru~ administration~ 
No drug 
Experimental groups 
MTX day 0, LV day 1 
MTX day 1, LV day 2 
MTX day 2, LV 4 hr before death 
Control groups 
MTX +  LV, day 2 
LV day 0 
MTX 1 day before SRBC, LV day 0 
MTX day 1, no LV 
Plaques/10  6  spleen cells 
Mean logs  Antilog 
5.4  42 
5. I  34 
0.7  1.6 
3.9  15 
4.8  28 
4.8  28 
6.8  111 
1.2  2.3 
No. of mice 
19 
10 
14 
7 
13 
5 
10 
5 
* All mice received 4 X  108 SRBC on day 0. 
:~ Methotrexate, 25 mg/kg body weight; and leucovorin, 25-35 mg/kg. 
comes susceptible to MTX 1 day after the initial antigen injection. MTX  ad- 
ministered at the time of the initial injection had no effect on the ability of mice 
to respond to a second dose of antigen, but MTX injected 1 day after antigen 
diminished the response to a second injection given on day 2. 
The experiment shown in Fig. 1, B suggested that priming has two phases: a 
nonproliferative phase,  approximately 1 day long, followed by a  proliferative 
phase. To confirm the nonproliferative nature of the first phase, we altered the 
regimen, administering the second injection of SRBC just 1 day after the pri- 
mary injection.  When MTX was administered along with the primary injec- 
tion, the 1 day priming was not inhibited (Table III). 
Although  there is no doubt that MTX inhibits proliferation, its metabolic 
effects are not restricted to inhibition of thymidine synthesis (11). To support 
our contention that the inhibitory effect of MTX is due to prevention of cell PATRICIA BYFIELD AND ELI  SERCARZ  901 
division, we did some preliminary experiments employing hydroxyurea, a drug 
which inhibits DNA synthesis quite specifically (15). Hydroxyurea mimics the 
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FIG. 1, A and B. Effect of methotrexate (MTX) on the primary and secondary responses, 
plaques per million nucleated spleen cells on day 4. Mice received MTX  (25 mg/kg) on the 
day indicated on the abscissa, and leucovorin (35 mg/kg) 24 hr later. 
Fig. I, A. Primary  response to 2 X  10  e sheep et~Lhrocytes. 
FI¢.  1, B. Secondary response. Mice received 2 X  10  6 SRBC on day 0 and 4 X  10  s SRBC 
on day 2. The clear bus indicate  controls not injected with drugs; hatched bars indicate 
~nim~ treated with MTX after a primary antigen injection; and, black bars indicate animals 
treated with MTX after a secondary antigen injection. 
effects of MTX:  it inhibits the secondary response but is without effect on the 
1st day of priming. 
Specificity of Memory.--To  show that memory was specific for the priming 
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burro erythrocytes,  which cross-react  only slightly  with sheep or goat erythro- 
cytes,  has no effect  on the subsequent 2-day response to sheep RBC  (Table IV, 
TABLE  III 
Lack of Effect of Methotrexate on 1-Day Priming* 
Plaques/10  s  spleen  cells 
Drug administration  No. of mice 
Mean log~  Antilog 
None  5.3  39  19 
MTX day 0:~  5.0  32  17 
* Both groups of mice received 2 X  108 SRBC on day 0 and 4 X  l0  s SRBC on day 1. 
The plaque assay was performed on day 3. 
Mice received 25 mg/kg body weight methotrexate, intraperitoneally,  at the same time 
as the first antigen injection, and 35 mg/kg leucovorin a few hours before the second injection 
of SRBC. 
TABLE IV 
Antigen Specifwity of Short-Term Memory 
Antigen  injections 
Day0:2 X 10*RBC  [  Day 2:4X10  sRBC 
Experiment 1" 
(a)  --  Sheep 
(b)  Burro  Sheep 
(c) Burro  Burro 
(d)  Burro  Burro +  sheep 
Experiment 2" 
(e)  --  Goat 
(f)  Burro  Burro +  goat 
For reference 
(g)  Sheep  Sheep 
Type of RBC 
used in assay 
Sheep 
Sheep 
Sheep 
Sheep 
Goat 
Goat 
Sheep 
Plaques/lO  s spleen cells  Memory 
on day 4 
Mean log~  [ 
2.0 
2.7 
0.8 
4.3 
4.0 
4.6 
6.8 
,ntilog  Plaques/10s 
spleen cells 
4.0 
6.5  2.5 
1.7  0 
20.0  14.0 
16.0 
24.0 
110.0 
6.0 
95.0 
* There were five to seven mice in each group. 
a  and b). During a specific secondary response to burro erythrocytes, there is a 
slight stimulation of the response to sheep or goat erythrocytes (Table IV, d 
and f). The increment  is small, however, compared with specific memory (Table 
IV, g). 
Time of Assay.--After  a short priming interval, the secondary IgM response PATRICIA  BYFIELD  AND  ELI  SERCARZ  903 
reaches a very sharp peak between the 2nd and 3rd days (9), a fact which some 
have overlooked. To avoid inaccuracy caused by missing  this sharp peak, we 
measured the response before the peak in all cases. Thus we may be measuring 
the delay or diminution of the peak response,  or some combination of the two. 
Both effects have been noted by Rivarola, et al. (16) depending upon the dose 
regimen  of MTX.  In  limited  experiments,  we found  no  evidence of delay. 
Either delay or diminution, however, would be a valid measure of inhibition of 
the response. 
DISCUSSION 
During the 1st day after primary antigen injection, a mouse does not produce 
detectable plaque-forming cells, but it does develop the ability to respond with 
rapid proliferation and antibody production to a second injection of antigen. 
Methotrexate has no effect on the priming which occurs during the 1st day. 
During the 2nd day after injection of SRBC, the short-term memory continues 
to increase;  this  increase  can be inhibited  by MTX.  Priming  thus has  two 
phases: the first, comprising  approximately 1 day, does not require cell division, 
but rather some qualitative change in cells; the second consists of proliferation 
of some or all of these altered cells. 
The phases which we have measured separately as the responses  to two in- 
jections of antigen may be identical to those normally occurring in the primary 
response. The greater rapidity and magnitude of the primary response to a large 
dose of antigen (Table I, and references  9 and 17) can be explained  as follows. 
The first contact of antigen-sensitive cells (X cells) with antigen leads to de- 
velopment of cells (Y cells) which are capable of reacting to further  antigen 
contact by very rapid  proliferation  and production of  antibody (9).  In  our 
system, the opportunity for further  antigen contact is minimal  after the low 
primary dose, unless a second injection is given.  After the hig/~ primary dose, 
enough antigen will remain to induce nearly maximal division and antibody pro- 
duction. This view is supported by our findings, shown in Table I, that (a) mice 
receiving a second dose 1 day after the low primary dose respond as well as 
animals receiving  the high primary dose; (b) a second injection 1 day after the 
high primary injection causes only a small  enhancement of the response;  and 
(c) even the low doses, if given dally, can induce a vigorous response.  None of 
these findings is predicted by the hypothesis that cells, once triggered,  respond 
in a predetermined manner for a predetermined time and can no longer be af- 
fected by antigen contact. Clearly,  the IgM-producing cell is still responsive to 
further antigenic contact (19, 20, 10). An injection just before the peak of a sec- 
ondary IgM response can prolong the increase of IgM plaques (21). 
Radioautographic examination of plaque-forming cells which have been ex- 
posed to isotopically labeled thymidine in vitro or in vivo have led to various 
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ent 3 or 4 days after antigenic stimulation have not synthesized a complement 
of DNA at any time since the antigen administration  (22, 23).  Other studies 
have indicated that all plaque-forming  cells arise from dividing precursors after 
the 2nd day (24, 25). Most of these studies have not been designed  to measure 
the rate of division. Those which have attempted to measure the cell cycle time 
have not agreed: Koros et al. (18) found a generation time of approximately 7 
hr, while Tannenberg calculated 13 hr (26). 
Studies utilizing  inhibitors of replication are difficult  to interpret,  owing to 
the problems of dosage, morbidity, and indirect effects. We have tried to avoid 
this problem insofar as possible by limiting the duration of the drug effect. Most 
inhibition  studies indicate that  cell  division is necessary for the increase  in 
plaque-forming  ceils  (27-30).  Rowley et  al.  measured  the  disappearance  of 
plaques  after  administration  of vinblastine  or  colchicine,  and  found  a  cell 
cycle time, approximately equal to the plaque number doubling time, of 5-10 
hr after the 2nd day of the response (31). Perhaps the clearest demonstration 
that cell division is required for the immune response is that of Dutton and 
Mishell (32) who caused dividing ceils to incorporate a lethal dose of tritiated 
thymidine, thereby preventing a response  by cultured mouse spleen ceils, un- 
less the "hot pulse" was restricted to the 1st day after antigen administration. 
Uyeki (33) showed that MTX inhibits the response  in vivo if given on the 2nd 
day after  antigen administration,  but not if given along  with antigen, and we 
have found the same. 
Our evidence indicates a qualitative difference  between the ceils which re- 
spond to primary and secondary injections; i.e., X  and Y cells. On the basis of 
entirely different evidence,  others have come to the same conclusion  (34, 35). 
We have found that a second administration of antigen within a few days after 
the prlm~ug dose causes plaque-forming  ceils  to increase  rapidly.  The  con- 
siderable increase which occurs within 1 day is due to proliferation, as it is in- 
hibited by methotrexate. On the contrary, events of the 1st day after the pri- 
mary injection of SRBC are not inhibited by methotrexate nor by hydroxyurea. 
Apparently, the preparatory events of the 1st day postprimary need not be 
repeated after the second injection. These events undoubtedly include macro- 
phage processing and distribution of antigen,  although these processes probably 
require only a short time, on the order of 1 hr (36-38). Other events may in- 
clude preparation for division, interaction of thymus-derived and bone marrow- 
derived cells (39), and morphological  changes (40, 41). We have suggested that 
(additional)  receptor molecules synthesized during the 1st day might mediate 
an interaction of ceils and antigen leading to immediate proliferation (9). 
We emphasize  that  the immediate proliferative response  to reinjection  of 
antigen  applies  to short-term  IgM memory only. Short-term memory wanes 
approximately 1 month after priming  (9,  10). Recently described phenomena 
in other systems (42, 43) parallel  our finding, but are not exactly comparable. PATRICIA BYFIELD AND ELI SERCARZ  905 
However, the results of O'Brien and Coons (44) and our own preliminary re- 
suits indicate that the secondary response after long priming intervals includes 
a nonproliferative lag phase. We are currently engaged in experiments designed 
to confirm or deny the existence of two varieties of IgM memory, and to com- 
pare IgM and IgG memory. 
SUMM~.RY 
Short-term IgM memory is established within I day after primary injection. 
This I day priming is independent of cell division as it can take place in the pres- 
sence d  methotrexate or hydroxyurea. 
The primary response involves a similar I day nonproliferative phase. On the 
contrary, cells responding to a second injection of antigen after short priming 
intervals begin to proliferate within hours. This implies a qualitative difference 
between the antigen-sensitive ceils in primed and normal animals. 
After I  day, further proliferative expansion of memory can occur, which is 
probably antigen dependent. The response to several dose regimens indicates 
that repeated antigenic contact is needed to maintain the IgM response. 
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